Genmab to showcase strength and breadth of comprehensive epcoritamab-bysp development program at 2024 american society of hematology (ash) annual meeting

Copenhagen, denmark--(business wire)--genmab a/s (nasdaq: gmab): more than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-hodgkin's lymphoma (nhl) patients new and updated data from epcore® clinical trial program reinforce the potential of epcoritamab as a monotherapy and in combination to treat multiple b-cell malignancies across lines of therapy genmab a/s (nasdaq: gmab) announced today more than 20 abstracts evaluating epc.
ASH Ratings Summary
ASH Quant Ranking